AWA
JAZZ icon

Acorn Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Acorn Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6
Closed -$1K – 666
2018
Q1 		$1K Hold
6
– – ﹤0.01% 801
2017
Q4 		$1K Buy
+6
New +$832 ﹤0.01% 766

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Acorn Wealth Advisors's JAZZ Position: Q2 2018 in Review

Acorn Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2018, closing a stake of 6 shares — an estimated $1K sold.

Acorn Wealth Advisors first reported a position in JAZZ in Q4 2017 and held it in 2 quarters. The position peaked at $1K in Q1 2018. 376 funds tracked by Wall St. Rank hold JAZZ as of Q2 2018.

  • Acorn Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Acorn Wealth Advisors sold 6 Jazz Pharmaceuticals shares in Q2 2018, an estimated $1K.
  • Acorn Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Acorn Wealth Advisors's Jazz Pharmaceuticals position peaked at $1K in Q1 2018.
  • 376 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2018.

Based on Acorn Wealth Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.